Literature DB >> 17426441

LS14 cells: a model for chemoresistance in liposarcoma.

Elizabeth W LaPensee1, Shamantha P Reddy, Eric R Hugo, Sandy J Schwemberger, Nira Ben-Jonathan.   

Abstract

Liposarcoma, a malignancy of adipose tissue, is the most common soft tissue sarcoma. Patients whose primary tumor cannot be resected or those who have developed metastasis, have poor prognosis since liposarcomas are highly resistant to chemotherapy. We recently generated a spontaneously immortalized cell line, named LS14, from a patient with metastatic liposarcoma. Our goal was to compare the responsiveness of LS14 and SW872 liposarcoma cells to anti-cancer drugs and explore mechanisms of chemoresistance. Using complementary assays for cell viability and number we found that SW872 cells responded robustly to relatively low concentrations of doxorubicin, cisplatin and vinblastine. This reduction in cell viability was due to apoptosis, as evident by phosphatidylserine exposure and caspase 3 cleavage. In contrast, only a high dose of doxorubicin or combination therapy effectively reduced LS14 cell viability and induced apoptosis. LS14 cells showed a higher expression of Bcl-2 and Bcl-xL, but a lower expression of survivin and Bax, than SW872 cells, suggesting that anti-apoptotic proteins contribute to chemoresistance in LS14 cells. Although LS14 cells did not form colonies in soft agar, they generated large tumors and metastases in SCID mice, establishing their tumorigenicity in vivo. In conclusion, LS14 cells are much more resistant to chemotherapy than SW872 cells, making them an excellent model for exploring the efficacy and mechanism of action of anti-cancer drugs in liposarcomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17426441     DOI: 10.4161/cbt.6.4.3816

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  3 in total

1.  Doxorubicin resistance in a novel in vitro model of human pleomorphic liposarcoma associated with alternative lengthening of telomeres.

Authors:  Marcy A Mitchell; Jay E Johnson; Kara Pascarelli; Neil Beeharry; Maria Chiourea; Sarantis Gagos; Dina Lev; Margaret von Mehren; David Kipling; Dominique Broccoli
Journal:  Mol Cancer Ther       Date:  2010-03-02       Impact factor: 6.261

2.  Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase.

Authors:  Elizabeth W LaPensee; Sandy J Schwemberger; Christopher R LaPensee; El Mustapha Bahassi; Scott E Afton; Nira Ben-Jonathan
Journal:  Carcinogenesis       Date:  2009-05-14       Impact factor: 4.944

3.  Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment.

Authors:  Christian Vay; Philipp M Schlünder; Levent Dizdar; Irene Esposito; Markus P H Ghadimi; Wolfram T Knoefel; Andreas Krieg
Journal:  J Cancer Res Clin Oncol       Date:  2021-12-03       Impact factor: 4.322

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.